Inovio Pharmaceuticals Stock Forecast, Price & News

Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions

Is Inovio Pharmaceuticals a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Inovio Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INO, but not buy additional shares or sell existing shares.
View analyst ratings for Inovio Pharmaceuticals or view top-rated stocks.

How has Inovio Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Inovio Pharmaceuticals' stock was trading at $8.37 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INO shares have decreased by 54.1% and is now trading at $3.84.
View which stocks have been most impacted by COVID-19.

When is Inovio Pharmaceuticals' next earnings date?

Inovio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Inovio Pharmaceuticals.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.33) by $0.04. The biopharmaceutical company earned $0.29 million during the quarter, compared to analyst estimates of $0.19 million. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 44.10% and a negative net margin of 3,391.88%. During the same period last year, the business posted ($0.22) EPS.
View Inovio Pharmaceuticals' earnings history.

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Shares of Inovio Pharmaceuticals reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for INO?

6 brokerages have issued twelve-month price targets for Inovio Pharmaceuticals' shares. Their forecasts range from $6.00 to $35.00. On average, they expect Inovio Pharmaceuticals' share price to reach $12.60 in the next twelve months. This suggests a possible upside of 228.1% from the stock's current price.
View analysts' price targets for Inovio Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the following people:

• J. Joseph Kim, President, Chief Executive Officer & Director
• Jacqueline E. Shea, Chief Operating Officer & Executive Vice President
• Peter D. Kies, Chief Financial Officer
• Stephen Kemmerrer, Senior Vice President-Engineering Development
• Kate E. Broderick, Senior Vice President-Research & Development

What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?

12 employees have rated Inovio Pharmaceuticals CEO J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among Inovio Pharmaceuticals' employees.

Who are some of Inovio Pharmaceuticals' key competitors?

Some companies that are related to Inovio Pharmaceuticals include Merit Medical Systems (MMSI), NuVasive (NUVA), AtriCure (ATRC), Haemonetics (HAE), Nevro (NVRO), Glaukos (GKOS), Axonics (AXNX), Beauty Health (SKIN), Atrion (ATRI), Paragon 28 (FNA), Silk Road Medical (SILK), Bioventus (BVS), Alphatec (ATEC), OrthoPediatrics (KIDS) and Treace Medical Concepts (TMCI).
View all of INO's competitors.

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Green Alpha Advisors LLC (0.03%), Aries Wealth Management (0.03%), Cutler Group LP (0.00%) and Stratos Wealth Partners LTD. (0.01%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies and Simon X Benito.
View institutional ownership trends for Inovio Pharmaceuticals.

Which major investors are selling Inovio Pharmaceuticals stock?

INO stock was sold by a variety of institutional investors in the last quarter, including Stratos Wealth Partners LTD.. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies, and Simon X Benito.
View insider buying and selling activity for Inovio Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Inovio Pharmaceuticals stock?

INO stock was acquired by a variety of institutional investors in the last quarter, including Aries Wealth Management, Cutler Group LP, and Green Alpha Advisors LLC.
View insider buying and selling activity for Inovio Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inovio Pharmaceuticals' stock price today?

One share of INO stock can currently be purchased for approximately $3.84.

How much money does Inovio Pharmaceuticals make?

Inovio Pharmaceuticals has a market capitalization of $807.88 million and generates $7.41 million in revenue each year. The biopharmaceutical company earns $-166.41 million in net income (profit) each year or ($1.09) on an earnings per share basis.

How many employees does Inovio Pharmaceuticals have?

Inovio Pharmaceuticals employs 262 workers across the globe.

When was Inovio Pharmaceuticals founded?

Inovio Pharmaceuticals was founded in 1979.

What is Inovio Pharmaceuticals' official website?

The official website for Inovio Pharmaceuticals is www.inovio.com.

Where are Inovio Pharmaceuticals' headquarters?

Inovio Pharmaceuticals is headquartered at 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at (267) 440-4200, via email at [email protected], or via fax at 267-440-4242.